277 related articles for article (PubMed ID: 25851099)
1. Safinamide: first global approval.
Deeks ED
Drugs; 2015 Apr; 75(6):705-11. PubMed ID: 25851099
[TBL] [Abstract][Full Text] [Related]
2. Clinical pharmacology review of safinamide for the treatment of Parkinson's disease.
Fabbri M; Rosa MM; Abreu D; Ferreira JJ
Neurodegener Dis Manag; 2015 Dec; 5(6):481-96. PubMed ID: 26587996
[TBL] [Abstract][Full Text] [Related]
3. Safinamide: A Review in Parkinson's Disease.
Blair HA; Dhillon S
CNS Drugs; 2017 Feb; 31(2):169-176. PubMed ID: 28110399
[TBL] [Abstract][Full Text] [Related]
4. Long-term efficacy and safety of safinamide as add-on therapy in early Parkinson's disease.
Schapira AH; Stocchi F; Borgohain R; Onofrj M; Bhatt M; Lorenzana P; Lucini V; Giuliani R; Anand R;
Eur J Neurol; 2013 Feb; 20(2):271-80. PubMed ID: 22967035
[TBL] [Abstract][Full Text] [Related]
5. Long-Term Effects of Safinamide on Dyskinesia in Mid- to Late-Stage Parkinson's Disease: A Post-Hoc Analysis.
Cattaneo C; Ferla RL; Bonizzoni E; Sardina M
J Parkinsons Dis; 2015; 5(3):475-81. PubMed ID: 26406127
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic drug evaluation of safinamide mesylate for the treatment of mid-to-late stage Parkinson's disease.
Müller T
Expert Opin Drug Metab Toxicol; 2017 Jun; 13(6):693-699. PubMed ID: 28537214
[TBL] [Abstract][Full Text] [Related]
7. Safinamide for the treatment of Parkinson's disease.
Kandadai RM; Jabeen SA; Kanikannan MA; Borgohain R
Expert Rev Clin Pharmacol; 2014 Nov; 7(6):747-59. PubMed ID: 25300164
[TBL] [Abstract][Full Text] [Related]
8. Safinamide (Xadago) for Parkinson's disease.
Med Lett Drugs Ther; 2017 Sep; 59(1529):151-153. PubMed ID: 28880847
[No Abstract] [Full Text] [Related]
9. Safinamide: FCE 26743, NW 1015, PNU 151774, PNU 151774E.
Drugs R D; 2004; 5(6):355-8. PubMed ID: 15563241
[TBL] [Abstract][Full Text] [Related]
10. Safinamide for the treatment of Parkinson's disease.
deSouza RM; Schapira A
Expert Opin Pharmacother; 2017 Jun; 18(9):937-943. PubMed ID: 28504022
[TBL] [Abstract][Full Text] [Related]
11. Clinical Pharmacokinetics and Pharmacodynamics of Safinamide.
Müller T; Foley P
Clin Pharmacokinet; 2017 Mar; 56(3):251-261. PubMed ID: 27665574
[TBL] [Abstract][Full Text] [Related]
12. [Effectiveness and safety of safinamide as add-on to levodopa in patients with parkinson's disease: non-interventional study].
Jost WH; Kupsch A; Mengs J; Delf M; Bosse D
Fortschr Neurol Psychiatr; 2018 Oct; 86(10):624-634. PubMed ID: 30142650
[TBL] [Abstract][Full Text] [Related]
13. A randomized, double-blind, placebo-controlled trial of safinamide as add-on therapy in early Parkinson's disease patients.
Stocchi F; Borgohain R; Onofrj M; Schapira AH; Bhatt M; Lucini V; Giuliani R; Anand R;
Mov Disord; 2012 Jan; 27(1):106-12. PubMed ID: 21913224
[TBL] [Abstract][Full Text] [Related]
14. Safinamide (Newron Pharmaceuticals).
Chazot PL
Curr Opin Investig Drugs; 2001 Jun; 2(6):809-13. PubMed ID: 11572661
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant therapies for Parkinson's disease: critical evaluation of safinamide.
Stocchi F; Torti M
Drug Des Devel Ther; 2016; 10():609-18. PubMed ID: 26917951
[TBL] [Abstract][Full Text] [Related]
16. Safinamide as Add-On Therapy to Levodopa in Mid- to Late-Stage Parkinson's Disease Fluctuating Patients: Post hoc Analyses of Studies 016 and SETTLE.
Cattaneo C; Sardina M; Bonizzoni E
J Parkinsons Dis; 2016; 6(1):165-73. PubMed ID: 26889632
[TBL] [Abstract][Full Text] [Related]
17. Current status of safinamide for the drug portfolio of Parkinson's disease therapy.
Müller T
Expert Rev Neurother; 2013 Sep; 13(9):969-77. PubMed ID: 24053341
[TBL] [Abstract][Full Text] [Related]
18. ▼ Safinamide for Parkinson's disease.
Drug Ther Bull; 2018 May; 56(5):54-57. PubMed ID: 29760163
[TBL] [Abstract][Full Text] [Related]
19. Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson's disease.
Borgohain R; Szasz J; Stanzione P; Meshram C; Bhatt MH; Chirilineau D; Stocchi F; Lucini V; Giuliani R; Forrest E; Rice P; Anand R;
Mov Disord; 2014 Sep; 29(10):1273-80. PubMed ID: 25044402
[TBL] [Abstract][Full Text] [Related]
20. Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations.
Borgohain R; Szasz J; Stanzione P; Meshram C; Bhatt M; Chirilineau D; Stocchi F; Lucini V; Giuliani R; Forrest E; Rice P; Anand R;
Mov Disord; 2014 Feb; 29(2):229-37. PubMed ID: 24323641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
